Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using their proprietary ProCellEx® plant cell-based expression system, has announced their participation in the upcoming iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.

The virtual conference is scheduled for March 25-26, 2025, featuring a two-day format with webcast presentations on the first day and one-on-one meetings between Protalix management and pre-qualified investors on the second day. The conference is organized by iAccess Alpha, which hosts virtual investor conferences for recommended companies.

Interested participants are advised to join the call 15 minutes early to complete necessary technical preparations. A recording of the presentation will remain accessible for at least six months through the Events Calendar in the Investors section of Protalix's website.

Argus Session date unavailable

+4.42% session move Open Argus

Details

News Market Reaction – PLX

The recorded move for PLX in the trading session of this news was +4.42%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARMIEL, Israel, March 24, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^® plant cell–based protein expression system, today announced that its management will be participating in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, to be held virtually March 25-26, 2025.

iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between Protalix management and pre-qualified investors on Day 2.

For more information about the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, or to register and schedule a one-on-one meeting with Protalix, please visit the conference website at: https://www.iaccessalpha.com/home.

iAccess Alpha Virtual Best Ideas Spring Conference 2025

Live Presentation
Date:	Tuesday, March 25, 2025
Time:	12:00 p.m. Eastern Daylight Time (EDT)
Company Link:	https://ir.protalix.com/news-events/events
Webcast Link:	https://tinyurl.com/yekbs6k6

Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for at least six months on the Events Calendar of the Investors section of Protalix's website, at the above link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio^®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.

Investor Contact

Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com 

Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-iaccess-alpha-virtual-best-ideas-spring-conference-2025-302409050.html

SOURCE Protalix BioTherapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Protalix BioTherapeutics (PLX) presenting at the iAccess Alpha Conference 2025?

Protalix BioTherapeutics will present at the iAccess Alpha Virtual Best Ideas Spring Conference on March 25-26, 2025, with presentations on day 1 and one-on-one investor meetings on day 2.

What is the format of PLX's participation in the iAccess Alpha Conference 2025?

The format includes webcast presentations on the first day (March 25) and one-on-one meetings between Protalix management and pre-qualified investors on the second day (March 26).

How long will PLX's iAccess Alpha Conference presentation be available for replay?

The presentation replay will be available for at least six months on the Events Calendar of the Investors section of Protalix's website.

What technology does PLX use for protein production?

Protalix uses their proprietary ProCellEx® plant cell-based protein expression system for the development and production of recombinant therapeutic proteins.